{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:28:32Z","timestamp":1790818112566,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Both lipoprotein(a) [Lp(a)] and peripheral artery disease (PAD) are associated with ischaemic events. We sought to assess the association between Lp(a) and major adverse cardiovascular events (MACE) and major lower extremity events (MALE) among patients with baseline PAD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>The Mass General Brigham (MGB) Lp(a) registry includes all individuals with Lp(a) measured at two tertiary care centres from 2000 to 2019. Those with PAD were grouped according to Lp(a) percentile: 1st\u201325th [Q1, Lp(a) \u2264 14\u2005nmol\/L], 26th\u201350th (Q2, 14\u2013&amp;lt;42\u2005nmol\/L), 51st\u201375th (Q3, 42\u2013&amp;lt;132\u2005nmol\/L), and 76th\u2013100th (Q4, 132\u2013855\u2005nmol\/L). Outcomes were MACE [composite of cardiovascular (CV) death, myocardial infarction, or coronary revascularization] and MALE (composite of peripheral revascularization, acute limb ischaemia, or major lower extremity amputation). Cox proportional hazard modelling was used to assess the association between Lp(a) and the outcomes of interest after adjusting for traditional risk factors. Among 3757 individuals with PAD [39% female, median age 68 (IQR: 58\u201377)], individuals with Lp(a) levels in the third and fourth quartiles had a 24 and 30% increased hazard of MACE, respectively [adj. hazard ratio (HR): 1.24, P = 0.005; adj. HR: 1.30, P = 0.001] when compared with those in the first quartile. Individuals in the fourth quartile had a 19% greater hazard of MALE (adj. HR: 1.19, P = 0.043).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Elevated Lp(a) in patients with PAD was associated with an increased risk of both MACE and MALE. Accordingly, measurement of Lp(a) may convey important prognostic value and allow for further risk stratification within this high-risk population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf475","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T12:01:50Z","timestamp":1757073710000},"source":"Crossref","is-referenced-by-count":7,"title":["Association between lipoprotein(a) and cardiovascular events in patients with peripheral artery disease: the Mass General Brigham Lp(a) registry"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6559-023X","authenticated-orcid":false,"given":"Daniel J","family":"McClintick","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Biery","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"},{"name":"Albert Einstein College of Medicine , 1300 Morris Park, Bronx, NY 10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam N","family":"Berman","sequence":"additional","affiliation":[{"name":"Division of Cardiology, NYU Langone Health , 530 First Avenue, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Besser","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Shiyovich","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinainder","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M","family":"Huck","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany N","family":"Weber","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-7605","authenticated-orcid":false,"given":"Rhanderson","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P","family":"Bonaca","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Massachusetts General Hospital, Baim Institute for Clinical Research , 55 Fruit Street, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie D","family":"Gerhard-Herman","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo F","family":"Di Carli","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A","family":"Secemsky","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Beth Israel Deaconess Medical Center , 330 Brookline, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-6562","authenticated-orcid":false,"given":"Ron","family":"Blankstein","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0598-6502","authenticated-orcid":false,"given":"Sanjay","family":"Divakaran","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"2025091920404189500_zwaf475-B1","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"2025091920404189500_zwaf475-B2","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025091920404189500_zwaf475-B3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025091920404189500_zwaf475-B4","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.21037\/atm.2019.08.77","article-title":"Role of lipoprotein (a) in peripheral arterial disease","volume":"7","author":"Kosmas","year":"2019","journal-title":"Ann Transl Med"},{"key":"2025091920404189500_zwaf475-B5","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"key":"2025091920404189500_zwaf475-B6","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"2025091920404189500_zwaf475-B7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.atherosclerosis.2022.11.007","article-title":"Studies on lipoprotein(a) and outcomes in peripheral arterial disease: one must not compare apples with pears","volume":"363","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"2025091920404189500_zwaf475-B8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/clc.24003","article-title":"Association between lipoprotein(a) and peripheral arterial disease in coronary artery bypass grafting patients","volume":"46","author":"Yi","year":"2023","journal-title":"Clin Cardiol"},{"key":"2025091920404189500_zwaf475-B9","doi-asserted-by":"crossref","first-page":"e2245720","DOI":"10.1001\/jamanetworkopen.2022.45720","article-title":"Association of Lipoprotein(a) levels with incidence of major adverse limb events","volume":"5","author":"Guedon","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025091920404189500_zwaf475-B10","doi-asserted-by":"crossref","first-page":"e015355","DOI":"10.1161\/JAHA.119.015355","article-title":"Association of serum lipoprotein (a) with the requirement for a peripheral artery operation and the incidence of major adverse cardiovascular events in people with peripheral artery disease","volume":"9","author":"Golledge","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025091920404189500_zwaf475-B11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1358863X221091320","article-title":"Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: a systematic review","volume":"27","author":"Masson","year":"2022","journal-title":"Vasc Med"},{"key":"2025091920404189500_zwaf475-B12","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025091920404189500_zwaf475-B13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/clc.23456","article-title":"Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: design and rationale of the Mass General Brigham Lp(a) Registry","volume":"43","author":"Berman","year":"2020","journal-title":"Clin Cardiol"},{"key":"2025091920404189500_zwaf475-B14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease","volume":"83","author":"Berman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025091920404189500_zwaf475-B15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen city heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"2025091920404189500_zwaf475-B16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2025091920404189500_zwaf475-B17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated Lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025091920404189500_zwaf475-B18","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"2025091920404189500_zwaf475-B19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/CIRCULATIONAHA.123.066398","article-title":"Relating Lipoprotein(a) concentrations to cardiovascular event risk after acute coronary syndrome: a comparison of 3 tests","volume":"149","author":"Szarek","year":"2024","journal-title":"Circulation"},{"key":"2025091920404189500_zwaf475-B20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50\u2005mg\/dL (105\u2005nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025091920404189500_zwaf475-B21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12933-024-02348-2","article-title":"Lipoprotein(a) as a cardiovascular risk factor among patients with and without diabetes mellitus: the Mass General Brigham Lp(a) Registry","volume":"23","author":"Shiyovich","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2025091920404189500_zwaf475-B22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0895-4356(00)00272-9","article-title":"Validation of death certificate diagnosis for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study","volume":"54","author":"Coady","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"2025091920404189500_zwaf475-B23","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamacardio.2019.3891","article-title":"Association of cardiovascular disease with premature mortality in the United States","volume":"4","author":"Chen","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2025091920404189500_zwaf475-B24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1753-6405.2011.00739.x","article-title":"Accuracy of national mortality codes in identifying adjudicated cardiovascular deaths","volume":"35","author":"Harriss","year":"2011","journal-title":"Aust N Z J Public Health"},{"key":"2025091920404189500_zwaf475-B25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records","volume":"148","author":"Kiyota","year":"2004","journal-title":"Am Heart J"},{"key":"2025091920404189500_zwaf475-B26","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa0908610","article-title":"Population trends in the incidence and outcomes of acute myocardial infarction","volume":"362","author":"Yeh","year":"2010","journal-title":"N Engl J Med"},{"key":"2025091920404189500_zwaf475-B27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/pds.2312","article-title":"A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data","volume":"21","author":"Andrade","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025091920404189500_zwaf475-B28","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/01.mlr.0000160417.39497.a9","article-title":"Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors","volume":"43","author":"Birman-Deych","year":"2005","journal-title":"Med Care"},{"key":"2025091920404189500_zwaf475-B29","doi-asserted-by":"crossref","first-page":"k119","DOI":"10.1136\/bmj.k119","article-title":"Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study","volume":"360","author":"Patorno","year":"2018","journal-title":"BMJ"},{"key":"2025091920404189500_zwaf475-B30","doi-asserted-by":"crossref","first-page":"e0218919","DOI":"10.1371\/journal.pone.0218919","article-title":"A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbria Data-Value Project","volume":"14","author":"Cozzolino","year":"2019","journal-title":"PLoS One"},{"key":"2025091920404189500_zwaf475-B31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors","year":"2009","journal-title":"JAMA"},{"key":"2025091920404189500_zwaf475-B32","doi-asserted-by":"crossref","first-page":"100585","DOI":"10.1016\/j.jlr.2024.100585","article-title":"Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease","volume":"65","author":"Bellomo","year":"2024","journal-title":"J Lipid Res"},{"key":"2025091920404189500_zwaf475-B33","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Lau","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2025091920404189500_zwaf475-B34","first-page":"e563","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"2025091920404189500_zwaf475-B35","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants","volume":"55","author":"Erqou","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2025091920404189500_zwaf475-B36","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2025091920404189500_zwaf475-B37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"2025091920404189500_zwaf475-B38","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"key":"2025091920404189500_zwaf475-B39","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical trial design for Lipoprotein(a)-lowering therapies: JACC Focus Seminar 2\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025091920404189500_zwaf475-B40","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"2025091920404189500_zwaf475-B41","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025091920404189500_zwaf475-B42","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/ATVBAHA.124.319483","article-title":"Lipoprotein(a) in the year 2024: a look back and a look ahead","volume":"44","author":"Tsimikas","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025091920404189500_zwaf475-B43","doi-asserted-by":"crossref","first-page":"100886","DOI":"10.1016\/j.ajpc.2024.100886","article-title":"Lipoprotein (a) testing patterns among subjects with a measured lipid panel: the Mayo Clinic experience","volume":"20","author":"Manzato","year":"2024","journal-title":"Am J Prev Cardiol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf475\/64316945\/zwaf475.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf475\/64316945\/zwaf475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:40:51Z","timestamp":1758328851000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwaf475\/8257720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf475","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"zwaf475"}}